Skip to content

Total Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$86.48B-6.4%
Pfizer logo
PfizerPFE
$207.62B-0.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$789.02M+19.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$997M-13.8%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$925.67M-4.2%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$3.47B+143%
Enterprise value$3.34B+156%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0.0×
Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enliven Therapeutics's total assets?
Enliven Therapeutics (ELVN) reported total assets of $464.85M in Q1 2026.
How has Enliven Therapeutics's total assets changed year-over-year?
Enliven Therapeutics's total assets increased by 53.6% year-over-year, from $302.57M to $464.85M.
What is the long-term trend for Enliven Therapeutics's total assets?
Over 5 years (2020 to 2025), Enliven Therapeutics's total assets has grown at a 39.3% compound annual growth rate (CAGR), from $90.84M to $476.17M.
What does total assets mean?
The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.